RGEN vs. EXEL, HALO, NBIX, DNLI, ADPT, BIIB, QGEN, TECH, PCVX, and RVMD
Should you be buying Repligen stock or one of its competitors? The main competitors of Repligen include Exelixis (EXEL), Halozyme Therapeutics (HALO), Neurocrine Biosciences (NBIX), Denali Therapeutics (DNLI), Adaptive Biotechnologies (ADPT), Biogen (BIIB), Qiagen (QGEN), Bio-Techne (TECH), Vaxcyte (PCVX), and Revolution Medicines (RVMD). These companies are all part of the "biological products, except diagnostic" industry.
Exelixis (NASDAQ:EXEL) and Repligen (NASDAQ:RGEN) are both mid-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their profitability, risk, earnings, dividends, valuation, analyst recommendations, community ranking, institutional ownership and media sentiment.
Exelixis has higher revenue and earnings than Repligen. Exelixis is trading at a lower price-to-earnings ratio than Repligen, indicating that it is currently the more affordable of the two stocks.
Exelixis has a beta of 0.57, suggesting that its stock price is 43% less volatile than the S&P 500. Comparatively, Repligen has a beta of 1.03, suggesting that its stock price is 3% more volatile than the S&P 500.
Exelixis presently has a consensus price target of $26.33, indicating a potential upside of 20.24%. Repligen has a consensus price target of $197.75, indicating a potential upside of 18.38%. Given Repligen's higher possible upside, equities research analysts clearly believe Exelixis is more favorable than Repligen.
In the previous week, Exelixis had 15 more articles in the media than Repligen. MarketBeat recorded 41 mentions for Exelixis and 26 mentions for Repligen. Repligen's average media sentiment score of 0.30 beat Exelixis' score of 0.05 indicating that Exelixis is being referred to more favorably in the media.
85.3% of Exelixis shares are owned by institutional investors. Comparatively, 97.6% of Repligen shares are owned by institutional investors. 2.9% of Exelixis shares are owned by company insiders. Comparatively, 1.2% of Repligen shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
Exelixis has a net margin of 11.10% compared to Exelixis' net margin of 2.44%. Repligen's return on equity of 8.85% beat Exelixis' return on equity.
Exelixis received 176 more outperform votes than Repligen when rated by MarketBeat users. Likewise, 68.20% of users gave Exelixis an outperform vote while only 68.08% of users gave Repligen an outperform vote.
Summary
Exelixis beats Repligen on 13 of the 18 factors compared between the two stocks.
Get Repligen News Delivered to You Automatically
Sign up to receive the latest news and ratings for RGEN and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding RGEN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Repligen Competitors List
Related Companies and Tools
